ImageneBio (IMA) EBITDA Margin (2020 - 2025)

ImageneBio has disclosed EBITDA Margin across 6 years of filings, most recently posting 749.38% for Q1 2025.

• EBITDA Margin for Q1 2025 came in at 749.38%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2025 was 845.85% (changed N/A YoY), and the FY2023 annual result was 736.36%, down 29119.0% from the prior year.
• EBITDA Margin came in at 749.38% for Q1 2025 at ImageneBio, down from 58.17% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 13.81% in Q4 2021 to a low of 5484.55% in Q2 2022.
• The 5-year median for EBITDA Margin is 372.57% (2021), against an average of 1039.0%.
• Across the five-year window, EBITDA Margin soared 4009535 bps in 2021 and slumped 512707 bps in 2022, its largest moves.
• ImageneBio's EBITDA Margin stood at 13.81% in 2021, then sank by 2108 bps to 277.32% in 2022, then tumbled by 1099 bps to 3324.43% in 2023, then surged by 98 bps to 58.17% in 2024, then slumped by 1188 bps to 749.38% in 2025.
• The last three EBITDA Margin figures came in at 749.38% (Q1 2025), 58.17% (Q3 2024), and 3324.43% (Q4 2023), per Business Quant data.